Regencell Bioscience [RGC] vs United Therapeutics [UTHR] Detailed Stock Comparison

Regencell Bioscience Holdings Ltd.

NASDAQ
Loading...

United Therapeutics Corporation

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Regencell Bioscience Holdings Ltd. wins in 1 metrics, United Therapeutics Corporation wins in 14 metrics, with 0 ties. United Therapeutics Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Regencell Bioscience Holdings Ltd. United Therapeutics Corporation Better
P/E Ratio (TTM) -3,258.62 20.60 United Therapeutics Corporation
Price-to-Book Ratio 2,929.00 3.53 United Therapeutics Corporation
Debt-to-Equity Ratio 11.20 0.53 United Therapeutics Corporation
PEG Ratio N/A 0.83 N/A
EV/EBITDA -3,921.47 13.90 United Therapeutics Corporation
Profit Margin (TTM) 0.00% 41.94% United Therapeutics Corporation
Operating Margin (TTM) 0.00% 45.23% United Therapeutics Corporation
EBITDA Margin (TTM) N/A 45.23% N/A
Return on Equity -54.81% 19.72% United Therapeutics Corporation
Return on Assets (TTM) -33.20% 12.44% United Therapeutics Corporation
Free Cash Flow (TTM) $-4.01M $1.04B United Therapeutics Corporation
1-Year Return 20.24% 92.68% United Therapeutics Corporation
Price-to-Sales Ratio (TTM) N/A 7.91 N/A
Enterprise Value $14.48B $22.28B United Therapeutics Corporation
EV/Revenue Ratio N/A 7.00 N/A
Gross Profit Margin (TTM) N/A 86.91% N/A
Revenue per Share (TTM) $0 $72 United Therapeutics Corporation
Earnings per Share (Diluted) $-0.01 $27.88 United Therapeutics Corporation
Beta (Stock Volatility) 2.25 0.75 United Therapeutics Corporation
Short % of Float 1.26% 8.58% Regencell Bioscience Holdings Ltd.

Regencell Bioscience Holdings Ltd. vs United Therapeutics Corporation Stock Performance Analysis

Loading Price Chart...

RGC
UTHR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Regencell Bioscience Holdings Ltd.-9.24%-20.10%-40.20%-24.65%-0.98%-16.80%
United Therapeutics Corporation0.66%0.90%-3.34%2.86%9.85%10.64%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Regencell Bioscience Holdings Ltd.20.24%2,888.89%6,625.00%6,625.00%6,625.00%6,625.00%
United Therapeutics Corporation92.68%137.11%205.88%434.68%903.79%2,026.01%

Performance & Financial Health Analysis: Regencell Bioscience Holdings Ltd. vs United Therapeutics Corporation

MetricRGCUTHR
Market Information
Market Cap i$14.00B$25.11B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i105,478464,464
90 Day Avg. Volume i162,743635,891
Last Close$17.09$549.57
52 Week Range$9.39 - $83.60$272.12 - $609.35
% from 52W High-79.56%-9.81%
All-Time High$950.00 (May 30, 2025)$609.35 (May 06, 2026)
% from All-Time High-98.20%-9.81%
Growth Metrics
Quarterly Revenue GrowthN/A0.07%
Quarterly Earnings GrowthN/A0.21%
Financial Health
Profit Margin (TTM) i0.00%0.42%
Operating Margin (TTM) i0.00%0.45%
Return on Equity (TTM) i-0.55%0.20%
Debt to Equity (MRQ) i11.200.53
Cash & Liquidity
Book Value per Share (MRQ)$0.01$162.60
Cash per Share (MRQ)$0.01$66.63
Operating Cash Flow (TTM) i$-3,113,576$1.56B
Levered Free Cash Flow (TTM) i$-1,507,277$583.20M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Regencell Bioscience Holdings Ltd. vs United Therapeutics Corporation

MetricRGC (Apr 24, 2026)UTHR (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-3,258.6220.60
Forward P/E iN/A16.87
PEG Ratio iN/A0.83
Price to Sales (TTM) iN/A7.91
Price to Book (MRQ) i2,929.003.53
Market Capitalization
Market Capitalization i$14.00B$25.11B
Enterprise Value i$14.48B$22.28B
Enterprise Value Metrics
Enterprise to Revenue iN/A7.00
Enterprise to EBITDA i-3,921.4713.90
Risk & Other Metrics
Beta i2.250.75
Book Value per Share (MRQ) i$0.01$162.60

Financial Statements Comparison: Regencell Bioscience Holdings Ltd. vs United Therapeutics Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricRGC (2024)UTHR (2025)
Revenue/Sales i03.18B
Cost of Goods Sold iN/A384.40M
COGS % of Revenue i-12.1%
Gross Profit iN/A2.80B
Gross Margin i-87.9%
Research & Development i1.07M550.00M
Operating Income (EBIT) i-4.74M1.52B
Operating Margin i-47.7%
EBITDA i-3.99M1.84B
EBITDA Margin i-57.9%
Pre-Tax Income i-4.36M1.71B
Pre-Tax Income % of Revenue i-53.9%
Income Tax i0379.20M
Income Tax % of Revenue i-11.9%
Net Income (Profit) i-4.36M1.33B
Profit Margin i-41.9%

Balance Sheet & Liquidity Metrics

MetricRGC (2024)UTHR (2025)
Cash & Equivalents i2.96M1.56B
Total Current Assets i8.11M3.70B
Total Current Assets % of Revenue i-116.3%
Total Current Liabilities i193,578560.60M
Total Current Liabilities % of Revenue i-17.6%
Long-Term Debt i25,934N/A
Long-Term Debt % of Revenue i-0.0%
Total Shareholders Equity i8.22M7.10B
Retained Earnings i-21.62M8.56B
Retained Earnings % of Revenue i-268.9%
Property, Plant & Equipment i84,7800

Cash Flow Statement Comparison

MetricRGC (2024)UTHR (2025)
Operating Cash Flow i-3.88M1.44B
Operating Cash Flow % of Revenue i-45.3%
Capital Expenditures i-5,376-520.50M
Free Cash Flow i-4.01M1.04B
FCF Margin i-32.5%
Debt Repayment iN/A-500.00M
Common Stock Repurchase iN/A-1.02B

Short Interest & Institutional Ownership Analysis

MetricRGCUTHR
Shares Short i700,5092.84M
Short Ratio i5.624.40
Short % of Float i1.26%8.58%
Shares Outstanding i494.49M43.64M
Float Shares i43.94M40.32M
% Held by Insiders i88.56%1.94%
% Held by Institutions i0.12%97.78%
% Held by Public i11.32%0.28%

Dividend Analysis & Yield Comparison: Regencell Bioscience Holdings Ltd. vs United Therapeutics Corporation

MetricRGCUTHR
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A